Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis)

Fitzcharles, Mary‐Ann; Baerwald, Christoph; Ablin, Jacob N.; Haüser, Winfried

doi:10.1007/s00482-015-0084-3

Cited by 125 publications

(94 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epidemiological studies indicate that about 9% of adult cannabis users will develop addiction, whereas adolescent's percentages of addiction is as high as 17% . A partial list of adverse effects can be found in Table …”

Section: Cannabis and Autoimmune Diseasesmentioning

confidence: 99%

“…Common side effects found in both reviews were dizziness, dry mouth, nausea, and light headedness. No serious adverse events were reported …”

Section: Cannabis and Autoimmune Diseasesmentioning

confidence: 99%

“…66 A partial list of adverse effects can be found in Table 1. [66][67][68][69]71 Subgroups adverse effects Rheumatic diseases. A Cochrane review and an additional systematic review set out to examine cannabinoids (among other substances in the Cochrane review) efficacy and tolerability in patients with RA (both reviews), fibromyalgia, back pain, and osteoarthritis (only the systemic review).…”

Section: Adverse Effectsmentioning

confidence: 99%

“…No serious adverse events were reported. 68,69 Adolescents. Cannabis consumption by adolescents has been linked to reduced educational attainment, an approximately twofold increase in the risk of schizophrenia and a decrease in intelligence quotient scores following prolonged use.…”

Section: Adverse Effectsmentioning

confidence: 99%

See 3 more Smart Citations

Medical cannabis: Another piece in the mosaic of autoimmunity?

Katz

Porat-Katz

et al. 2016

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Legalization of cannabis' medicinal use is rapidly increasing worldwide, raising the need to evaluate medical implications of cannabis. Currently, evidence supports cannabis and its active ingredients as immune-modulating agents, affecting T-cells, B-cells, monocytes, and microglia cells, causing an overall reduction in pro-inflammatory cytokine expression and an increase in anti-inflammatory cytokines. Due to the supporting evidence of cannabinoids as an immune-modulating agent, research focusing on cannabinoids and autoimmunity has emerged. Several clinical trials in multiple sclerosis, inflammatory bowel disease, and fibromyalgia suggest cannabis' effectiveness as an immune-modulator. However, contradicting results and lack of large-scale clinical trials obscure these results. Although lacking clinical research, in vitro and in vivo experiments in rheumatoid arthritis, diabetes type 1, and systemic sclerosis demonstrate a correlation between disease activity and cannabinoids.

show abstract

Section: Cannabis and Autoimmune Diseasesmentioning

confidence: 99%

“…Common side effects found in both reviews were dizziness, dry mouth, nausea, and light headedness. No serious adverse events were reported …”

Section: Cannabis and Autoimmune Diseasesmentioning

confidence: 99%

Section: Adverse Effectsmentioning

confidence: 99%

Section: Adverse Effectsmentioning

confidence: 99%

See 2 more Smart Citations

Medical cannabis: Another piece in the mosaic of autoimmunity?

Katz

Porat-Katz

et al. 2016

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Evidence in uncontrolled trials of efficacy of cannabinoids for FM symptoms, although inconsistent, has suggested benefits [87]. In double-blinded, placebo-controlled studies nabilone (0.5-1.0 mg before bedtime) after 4 weeks evoked a significant reduction in pain and anxiety and improvement in quality of life in FM patients [88,89].…”

Section: Cannabinoidsmentioning

confidence: 98%

Potential drug therapies for the treatment of fibromyalgia

Lawson

2016

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Modest improvement of health status in patients with FM has been observed with drugs targeting a diverse range of molecular mechanisms. No single drug, however, offered substantial efficacy against all the symptoms characteristic of FM. Identification of new and improved therapies for FM needs to address the heterogeneity of the condition, which suggests existence of patient subgroups, the relationship of central and peripheral aspects of the pathophysiology and a requirement of combination therapy with drugs targeting multiple molecular mechanisms.

show abstract